Lumakras (Sotorasib) for Lung Cancer

Overview
Lumakras is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. An FDA-approved test is necessary to confirm the presence of the KRAS G12C mutation before using this medication. Lumakras was granted accelerated approval based on overall response rate and duration of response, and continued approval may depend on verification of clinical benefit in ongoing trials. Lumakras is also known by its drug name, sotorasib.

Lumakras belongs to the KRAS inhibitor category. It is thought to work by specifically targeting the KRAS G12C protein, a common mutation found in certain types of cancer, including non-small cell lung cancer. By inhibiting this protein, Lumakras disrupts cancer cell growth and survival.

How do I take it?
Prescribing information states that Lumakras is taken orally once daily as tablets. The tablets should be swallowed whole, with or without food. Lumakras should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Lumakras include diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity (liver damage), and cough. Laboratory tests may show decreased lymphocytes (a type of white blood cell), decreased hemoglobin (a protein in red blood cells), increased aspartate aminotransferase (a liver enzyme), increased alanine aminotransferase (another liver enzyme), decreased calcium, increased alkaline phosphatase (an enzyme related to liver and bone health), increased urine protein, and decreased sodium.

Rare but serious side effects may include interstitial lung disease (a group of disorders causing lung scarring) or pneumonitis (lung inflammation). Individuals taking this drug should be monitored for new or worsening pulmonary symptoms and discontinue Lumakras if interstitial lung disease or pneumonitis is confirmed. Liver function tests should also be conducted regularly to monitor for hepatotoxicity.

For more information about this treatment, visit:

Label: Lumakras — Sotorasib Tablet, Coated — DailyMed

Lumakras — Drugs.com